Dana-Farber Cancer Institute is a nonprofit cancer research and treatment center based in Boston, Massachusetts. Founded in 1947 by Sidney Farber, it is a teaching affiliate of Harvard Medical School and an NCI-designated Comprehensive Cancer Center. Adult oncology care is provided in collaboration with Brigham and Women’s Hospital, and pediatric oncology care with Boston Children’s Hospital.
Dana-Farber conducts basic, translational, and clinical research across oncology and hematology, including precision medicine, immuno-oncology, and biomarker-guided therapies. The institute operates extensive clinical trials programs and collaborates with academic, government, and industry partners to advance drug discovery and development. Its activities span laboratory science, computational biology, and population sciences to inform prevention, diagnosis, and treatment of cancer.
Also known as Lank Center for Genitourinary Oncology and DFCI.
None yet. When a new project in the record names Dana-Farber as owner, partner or investor, it shows here.
Rina‑S 120 mg/m² Q3W achieved 45.9% ORR and 12.1‑month median DOR in 109 platinum‑resistant ovarian cancer patients; activity seen across FRα expression levels.
evERA Phase III: giredestrant+everolimus doubled median PFS in ESR1‑mutated patients and improved ITT PFS; OS immature; manageable safety; FDA review dates set for Nov 30 and Dec 18, 2026.
Tarlatamab (IMDELLTRA) plus durvalumab showed statistically significant OS, PFS and ORR benefits versus durvalumab alone in Phase 3 DeLLphi‑305 for first‑line maintenance ES‑SCLC.
Phase 3 BRUIN CLL-322 found adding pirtobrutinib to a two‑year venetoclax+rituximab regimen reduced progression or death by 45% versus venetoclax+rituximab alone.
FDA cleared PD‑1 plus HIF‑2α adjuvant regimens after Phase 3 showed 28% lower recurrence risk and 81% vs 74% 24‑month DFS; notable anemia, hypoxia and treatment discontinuations.
Phase 3 trial shows KEYTRUDA and WELIREG improve disease-free survival in RCC. FDA accepts priority review for adjuvant treatment. Safety profile consistent with previous studies.
